All In Biotech

BLA 761179 · Jazz Pharms

Rylaze

Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn · Intramuscular · Asparagine-specific Enzyme

NovelOrphan

CDER novel approval, Jun 30, 2021: To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen

Last checked: Nov 20, 2026Latest source record: Apr 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 30, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

37

12 Phase 3, 6 recruiting

FAERS reports

344

165 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2025.

RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. ( 1 )

Mechanism: Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of RYLAZE is based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore depend on an exogenous source of asparagine for survival.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 18, 2022 Supplement 1 · Efficacy OrphanLetterLabel
  • Jun 30, 2021 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • RYLAZE · ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN 10MG/0.5ML · INJECTABLE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Asparaginase Erwinia Chrysanthemi (Recombinant)" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use33
  • hyperammonaemia31
  • febrile neutropenia28
  • nausea26
  • hypersensitivity21
  • pancreatitis20
  • urticaria19
  • rash18
  • vomiting17
  • neutropenia15
  • anaphylactic reaction14
  • ammonia increased12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202244
202369
2024104
202584
202643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Rylaze (Asparaginase Erwinia-Rywn) · HCPCS J9021

2024 spending

$877K

Beneficiaries

n/a

25 claims

Per beneficiary

n/a

2024 ASP limit $51.88 per unit

View as table
YearSpending
2020$0
2021$0
2022$468,527
2023$474,942
2024$876,744

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.